{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:21:02Z","timestamp":1772900462968,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"crossref","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Thrombosis and Hemostasis Research Society","award":["Mentored Research Award"],"award-info":[{"award-number":["Mentored Research Award"]}]},{"DOI":"10.13039\/100000019","name":"National Hemophilia Foundation","doi-asserted-by":"crossref","award":["Shire Clinical Fellowship"],"award-info":[{"award-number":["Shire Clinical Fellowship"]}],"id":[{"id":"10.13039\/100000019","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00277-019-03860-2","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:02:41Z","timestamp":1574769761000},"page":"121-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-2309","authenticated-orcid":false,"given":"Ang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Warnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"3860_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P (2017) How I treat myeloma with new agents. Blood 130:1507\u20131513. https:\/\/doi.org\/10.1182\/blood-2017-05-743203","journal-title":"Blood"},{"key":"3860_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, Le Gal G, Tay J et al (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9:653\u2013663. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04215.x","journal-title":"J Thromb Haemost"},{"key":"3860_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","volume":"126","author":"RH White","year":"2010","unstructured":"White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Gammon H, Schmaltz S, Romano PS (2010) Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 126:61\u201367. https:\/\/doi.org\/10.1016\/j.thromres.2010.03.009","journal-title":"Thromb Res"},{"key":"3860_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99\u2013104. https:\/\/doi.org\/10.1016\/j.ahj.2004.02.013","journal-title":"Am Heart J"},{"key":"3860_CR5","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1161\/STROKEAHA.114.006316","volume":"45","author":"SA Jones","year":"2014","unstructured":"Jones SA, Gottesman RF, Shahar E, Wruck L, Rosamond WD (2014) Validity of hospital discharge diagnosis codes for stroke: the atherosclerosis risk in communities study. Stroke 45:3219\u20133225. https:\/\/doi.org\/10.1161\/STROKEAHA.114.006316","journal-title":"Stroke"},{"key":"3860_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","volume":"18","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Eckert L, Wang Y, Wang H, Cohen A (2013) Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 18:1321\u20131329. https:\/\/doi.org\/10.1634\/theoncologist.2013-0226","journal-title":"Oncologist"},{"key":"3860_CR7","unstructured":"National Cancer Institute NCI Comorbidity Index. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html"},{"key":"3860_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004","journal-title":"Med Care"},{"key":"3860_CR9","unstructured":"Chrischilles EA, Winiecki SK, Carnahan RM, et al. Mini-sentinel assessment protocol thromboembolic events after immunoglobulin administration. https:\/\/www.sentinelinitiative.org\/vaccines-blood-biologics\/assessments\/thromboembolic-events-after-immunoglobulin-administration"},{"key":"3860_CR10","unstructured":"Cancer Research Network Cancer Therapy Look-up Tables. https:\/\/crn.cancer.gov\/resources\/codes.html"},{"key":"3860_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC (2014) The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33:1242\u20131258. https:\/\/doi.org\/10.1002\/sim.5984","journal-title":"Stat Med"},{"key":"3860_CR12","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin PC (2016) Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med 35:5642\u20135655. https:\/\/doi.org\/10.1002\/sim.7084","journal-title":"Stat Med"},{"key":"3860_CR13","unstructured":"National Comprehensive Cancer Network (2018) Cancer-associated venous thromboembolic disease. VTE-A2"},{"key":"3860_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","volume":"115","author":"F Gay","year":"2010","unstructured":"Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115:1343\u20131350. https:\/\/doi.org\/10.1182\/blood-2009-08-239046","journal-title":"Blood"},{"key":"3860_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.10.018","volume":"70","author":"J Luo","year":"2017","unstructured":"Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.018","journal-title":"Eur J Cancer"},{"key":"3860_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ, UK NCRI Haemato-oncology Clinical Studies Group (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30687-9","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03860-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03860-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03860-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:38:28Z","timestamp":1606264708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03860-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03860-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"5 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The current study itself was conducted without funding from industry. AL reports grant funding from the Conquer Cancer Foundation Young Investigator Award, Hemostasis and Thrombosis Research Society Mentored Research Award supported by an independent medical educational grant from Shire, and National Hemophilia Foundation Shire Clinical Fellowship Award. Other authors report no relevant financial interests, activities, relationships, or affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained because this was a de-identified aggregate national claims database study where individual patient could not be identified and informed consent could not be obtained. The study was reviewed and considered exempt by the University of Washington Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of informed consent"}}]}}